Preetha Madhukumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Preetha Madhukumar has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Veronique Kiak Mien Tan
SingHealth Duke-NUS Breast Centre, Singapore 168582, Singapore
4 shared publications - Benita Kiat Tee Tan
Sengkang General Hospital
3 shared publications - Chow Yin Wong
Department of Breast Surgery, Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore
3 shared publications - Yirong Sim
Department of Breast Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore
3 shared publications - Fuh Yong Wong
National Cancer Centre Singapore
2 shared publications - Kong Wee Ong
Department of Breast Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore
2 shared publications
Latest Publications
- 25 April 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (6) , 1440-1446
Male breast cancer: a Singapore perspective
Introduction: Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to report our institutional experience of MBC across a 20 year period, analyse the survival outcome and prognosis of this group against female breast cancer patients treated at the same centre.Methods: Clinical, histopathological, treatment and survival data of male and female breast cancer patients treated between Jan 1999 and July 2019 at Singapore General Hospital and National Cancer Centre Singapore were identified and analysed.Results: Fifty‐seven male patients were identified. The median age at diagnosis was 63 years. Majority had invasive ductal carcinoma (86%) and presented at an early disease stage: 70.2% presented as Tis/T1/T2 and 49.1% had no axillary nodal involvement. 84.2% had a simple mastectomy with either a sentinel lymph node biopsy or axillary clearance. The median follow up was 5.69 years for males and 5.83 years for females. The median survival was 11.86 years for males and 16.3 years for females. At 5 years, overall survival (OS) was 69.9% (52.3–82.1%) and disease free survival (DFS) was 62.9% (44.9–76.5%) for males compared with OS 83.8% (83.21–84.39%) and DFS 74.5% (73.91–75.09%) for females.Conclusion: MBC remains understudied. Our institutional data indicates that good long term survival in South‐East Asian patients can be achieved with treatment protocols that are similar to female breast cancer. More prospective studies are required.
- 25 April 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (6) , 1440-1446
Male breast cancer: a Singapore perspective
Introduction: Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to report our institutional experience of MBC across a 20 year period, analyse the survival outcome and prognosis of this group against female breast cancer patients treated at the same centre.Methods: Clinical, histopathological, treatment and survival data of male and female breast cancer patients treated between Jan 1999 and July 2019 at Singapore General Hospital and National Cancer Centre Singapore were identified and analysed.Results: Fifty‐seven male patients were identified. The median age at diagnosis was 63 years. Majority had invasive ductal carcinoma (86%) and presented at an early disease stage: 70.2% presented as Tis/T1/T2 and 49.1% had no axillary nodal involvement. 84.2% had a simple mastectomy with either a sentinel lymph node biopsy or axillary clearance. The median follow up was 5.69 years for males and 5.83 years for females. The median survival was 11.86 years for males and 16.3 years for females. At 5 years, overall survival (OS) was 69.9% (52.3–82.1%) and disease free survival (DFS) was 62.9% (44.9–76.5%) for males compared with OS 83.8% (83.21–84.39%) and DFS 74.5% (73.91–75.09%) for females.Conclusion: MBC remains understudied. Our institutional data indicates that good long term survival in South‐East Asian patients can be achieved with treatment protocols that are similar to female breast cancer. More prospective studies are required.
- 9 March 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (1) , 121-138
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer
Background Neoadjuvant chemotherapy (NAC) plays an important role in the management of locally advanced breast cancer. It allows for downstaging of tumors, potentially allowing for breast conservation. NAC also allows for in-vivo testing of the tumors’ response to chemotherapy and provides important prognostic information. There are currently no clearly defined clinical models that incorporate imaging with clinical data to predict response to NAC. Thus, the aim of this work is to develop a predictive AI model based on routine CT imaging and clinical parameters to predict response to NAC. Methods The CT scans of 324 patients with NAC from multiple centers in Singapore were used in this study. Four different radiomics models were built for predicting pathological complete response (pCR): first two were based on textural features extracted from peri-tumoral and tumoral regions, the third model based on novel space-resolved radiomics which extract feature maps using voxel-based radiomics and the fourth model based on deep learning (DL). Clinical parameters were included to build a final prognostic model. Results The best performing models were based on space-resolved and DL approaches. Space-resolved radiomics improves the clinical AUCs of pCR prediction from 0.743 (0.650 to 0.831) to 0.775 (0.685 to 0.860) and our DL model improved it from 0.743 (0.650 to 0.831) to 0.772 (0.685 to 0.853). The tumoral radiomics model performs the worst with no improvement of the AUC from the clinical model. The peri-tumoral combined model gives moderate performance with an AUC of 0.765 (0.671 to 0.855). Conclusions Radiomics features extracted from diagnostic CT augment the predictive ability of pCR when combined with clinical features. The novel space-resolved radiomics and DL radiomics approaches outperformed conventional radiomics techniques.
- 9 March 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (1) , 121-138
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer
Background Neoadjuvant chemotherapy (NAC) plays an important role in the management of locally advanced breast cancer. It allows for downstaging of tumors, potentially allowing for breast conservation. NAC also allows for in-vivo testing of the tumors’ response to chemotherapy and provides important prognostic information. There are currently no clearly defined clinical models that incorporate imaging with clinical data to predict response to NAC. Thus, the aim of this work is to develop a predictive AI model based on routine CT imaging and clinical parameters to predict response to NAC. Methods The CT scans of 324 patients with NAC from multiple centers in Singapore were used in this study. Four different radiomics models were built for predicting pathological complete response (pCR): first two were based on textural features extracted from peri-tumoral and tumoral regions, the third model based on novel space-resolved radiomics which extract feature maps using voxel-based radiomics and the fourth model based on deep learning (DL). Clinical parameters were included to build a final prognostic model. Results The best performing models were based on space-resolved and DL approaches. Space-resolved radiomics improves the clinical AUCs of pCR prediction from 0.743 (0.650 to 0.831) to 0.775 (0.685 to 0.860) and our DL model improved it from 0.743 (0.650 to 0.831) to 0.772 (0.685 to 0.853). The tumoral radiomics model performs the worst with no improvement of the AUC from the clinical model. The peri-tumoral combined model gives moderate performance with an AUC of 0.765 (0.671 to 0.855). Conclusions Radiomics features extracted from diagnostic CT augment the predictive ability of pCR when combined with clinical features. The novel space-resolved radiomics and DL radiomics approaches outperformed conventional radiomics techniques.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Breast Cancer
- Vol. 25 (1) , 37-48
Atypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade On Surgical Excision
Bong TS, et al. J Breast Cancer. 2022 Feb;25(1):37-48. https://doi.org/10.4048/jbc.2022.25.e7
- 1 January 2022
- Published by XMLink in Journal of Breast Cancer
- Vol. 25 (1) , 37-48
Open AccessAtypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade On Surgical Excision
Bong TS, et al. J Breast Cancer. 2022 Feb;25(1):37-48. https://doi.org/10.4048/jbc.2022.25.e7
- 1 July 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (7) , 1320-1332
Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing
- 1 July 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (7) , 1320-1332
Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing
- 1 July 2004
- Published by Elsevier in Asian Journal of Surgery
- Vol. 27 (3) , 243-245
Intrahepatic Biliary Cystadenoma Presenting with Obstructive Jaundice
- 1 July 2004
- Published by Elsevier in Asian Journal of Surgery
- Vol. 27 (3) , 243-245
Intrahepatic Biliary Cystadenoma Presenting with Obstructive Jaundice